

»Frequently Asked Questions for Physicians

What is array CGH?

Array-based comparative genomic hybridization (array CGH), also called microarray analysis, is a new cytogenetic technology that evaluates areas of the human genome for gains or losses of chromosome segments at a higher resolution than traditional karyotyping. Array CGH detects gains or losses of DNA, also called *DNA dosage alterations*, that are 80 kilobases (kb) or larger, whereas traditional high-resolution chromosome analysis detects chromosome structure alterations at a resolution of 5 Megabases (Mb) or greater.

How does it work?

Segments of DNA called bacterial artificial chromosomes (BACs) that are 80-200 Kb in size are selected from public genome databases based upon their location in the genome. The BAC clones are predominantly selected to target areas of the human genome that, when deleted or duplicated, are known or highly suspected to cause well-characterized genetic conditions with mental retardation and/or birth defects. The BACs are carefully tested in-house by fluorescence in situ hybridization (FISH) for reliability. Microarray printers attach the BAC clones to a glass slide in an organized fashion to form a microarray. A typical microarray slide contains thousands of different BAC clones representing targeted areas of the genome. Fluorescently labeled DNA from both patient and a known normal human control are applied to the slide and compete to attach or *hybridize* to their corresponding BAC clone DNA segments. Computer software analyzes the fluorescent signals for areas of unequal hybridization of patient versus control DNA, signifying a DNA dosage alteration (deletion or duplication). The results are interpreted and reported by an ABMG board-certified cytogeneticist with expertise in array CGH.

Are there different types of array CGH?

Yes. Array CGH is used in both research and diagnostic testing. For diagnostic testing of patients with mental retardation, birth defects, behavioral problems, growth issues, etc., *targeted array CGH* is used. *Targeted* means that the areas of the genome that the microarray evaluates are selected as areas likely to be associated with known phenotypes. This is different from *whole genome arrays*, which are primarily used in research and contain BAC clones that are spaced at regular intervals throughout the genome without specific association with a known phenotype.

What types of abnormalities does array CGH detect?

Array CGH detects microscopic and submicroscopic deletions and duplications at targeted areas of the genome, including loci of known microdeletion/microduplication syndromes, subtelomeric regions, and pericentromeric regions. Array CGH will also identify marker chromosomes, some cases of mosaicism, and aneuploidy.

What will array CGH not detect?

Array CGH will not detect balanced chromosome rearrangements, such as balanced translocations or inversions. Array CGH will not detect alterations in chromosome structure at areas of the genome not covered by the array. This technology will not detect deletions or duplications that are smaller than 80 kb or point mutations within genes. Array CGH will not detect mosaicism at a level lower than 20%, nor will it detect some types of polyploidy, such as triploidy.

»Frequently Asked Questions for Physicians

I already order subtelomere probes on many of my patients. Why perform microarray testing instead of FISH with subtelomere probes?

Array CGH offers more comprehensive analysis of the subtelomeric regions and can identify terminal *and* interstitial deletions, whereas subtelomeric probes only identify terminal deletions. Furthermore, array CGH can help to determine the size of the subtelomere deletion or duplication. The SignatureChip[®] has on average > 5 Mb of coverage on each subtelomere. In our experience, an estimated 25% of subtelomeric alterations identified through our laboratory have been interstitial and would be missed by conventional subtelomeric probe analysis.

I have a patient with MCA and an apparently balanced de novo translocation. Can the SignatureChip[®] help determine whether it is really balanced?

Array CGH will not detect balanced rearrangements. This technology may detect submicroscopic deletions or duplications at a breakpoint if the breakpoint occurs in an area covered by the microarray. Please call our laboratory to discuss this type of case before sending a sample.

Does array CGH detect point mutations?

No. The limit of resolution depends on the size of the BAC. As a general rule, array CGH will not detect changes in DNA smaller than 80 kb.

Who is a candidate for array CGH?

Patients with or without prior genetic workup who have mental retardation of unknown etiology, congenital anomalies, dysmorphic features, a suspected syndrome with normal chromosomes/subtelomere FISH/other studies or stillbirth or fetal demise.

What about testing a pregnancy?

Prenatal cases in which karyotype or FISH analysis is warranted can benefit from the newly designed Signature PrenatalChip[™] in addition to traditional chromosome analysis. The Signature PrenatalChip[™] is specifically designed to enhance prenatal cytogenetic testing while minimizing the possibility of results of unclear clinical significance.

What is the likelihood of identifying an abnormality with array CGH?

Based on our experience with over 10,000 postnatal samples undergoing SignatureChip[®] analysis, approximately 7% of cases have a genomic alteration related to the abnormal phenotype of the patient.

How do you handle cases of unclear clinical significance?

Our microarrays are designed to minimize polymorphic alterations. In the event that a result of unclear clinical significance is found, the patient report will identify the finding as having unclear clinical relevance. Parental studies are offered at no additional cost. Signature Genomic Laboratories also participates in internal and external collaborations to define these regions and frequently publishes its findings in scientific journals.

»Frequently Asked Questions for Physicians

What are the detection rates for your clinical loci?

Detection rates vary from locus to locus. They are based on current peer-reviewed literature and are available at our web site with educational links at www.signaturegenomics.com. Board-certified genetic counselors are also available to discuss detection rates with you. For many loci tested by the SignatureChip® or Signature PrenatalChip™, a negative result does not exclude the suspected clinical diagnosis.

What types of samples are suitable for array CGH?

Array CGH is most commonly performed on whole blood samples. We require both a green-top sodium heparin tube and a purple-top EDTA tube. Array CGH can also be performed on cultured lymphocytes, cultured fibroblasts, placental tissue/POC, cultured amniotic fluid cells, cultured CVS samples, extracted DNA, and other samples. Please call the laboratory for more details.

Why do you need to know the gender of the patient?

Our laboratory uses built-in opposite-sex controls for quality assurance purposes. This means that we use a control genome of the opposite sex compared to the patient genome when we perform array CGH. This strategy ensures that the experiment has worked. Laboratories that use same-sex controls run the risk of interpreting a failed array CGH result as normal. Strategically placed BAC clones in the pseudoautosomal regions of the X and Y chromosomes ensure that array CGH will detect sex chromosome abnormalities such as 47, XXY (Ballif et al. *Prenat Diagn* 2006;26:333-339).

Does insurance cover testing?

Many insurance providers cover array CGH, and CPT codes have been established specifically for microarrays. We will bill private insurance companies. At this time, we are only able to accept Washington, Idaho and Montana Medicaid. Other methods of payment, including institutional billing and self-pay, are also available. Visit our web site for more details regarding payment options.

How can I get more information?

Visit our website at www.signaturegenomics.com, e-mail us at info@signaturegenomics.com, or call us at 1-877-SigChip.

In accordance with Washington State Law RCW 7.70.050 and WAC 388-531-0050, providing patients with the information necessary for them to be able to give their informed consent for testing or treatment is the responsibility of the health care provider who has direct contact with the patient. Laboratory tests are ordered and prescribed by physicians so it is the physician, not the laboratory, that is required to obtain the patient's informed consent for testing.

The contents of the **Frequently Asked Questions for Physicians**, **Frequently Asked Questions for Patients** and **Frequently Asked Questions for Prenatal Testing** are provided for informational purposes only and are not and should not be construed as medical advice, diagnosis, or treatment. Only a properly qualified physician can address specific questions regarding a patient's health care needs. Individual inquiries about medical or health care issues should be addressed to appropriate health care professionals. Nothing contained in the **Frequently Asked Questions for Physicians**, **Frequently Asked Questions for Patients** or **Frequently Asked Questions for Prenatal Testing** should be used to replace or substitute for a patient's personal physician's advice.